Pulmonary Drug Delivery Systems Market is Booming Growth Prospects, Incredible Demand and Business Strategies 2023-2030 | 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca
The pulmonary drug delivery systems market is witnessing high growth owing to the increasing prevalence of respiratory diseases globally. As per the World Health Organization, respiratory diseases accounted for over 4 million deaths in 2019. Chronic obstructive pulmonary disease (COPD) alone is projected to be the third leading cause of death worldwide by 2030. Moreover, factors such as rising geriatric population, growth in healthcare spending, and technological advancements in pulmonary drug delivery devices are also fueling the market growth during the forecast period. However, factors such as complex drug delivery mechanisms and availability of alternative drug delivery modes can hinder market growth.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/3952
The increasing prevalence of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis globally is one of the key factors driving the growth of the pulmonary drug delivery systems market. According to the Global Burden of Disease Study, around 251 million cases of asthma were reported worldwide in 2016. Similarly, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) estimates that over 330 million people suffer from COPD globally. Pulmonary drug delivery offers several advantages over traditional routes of drug administration for treating such respiratory diseases. These systems ensure direct delivery of drugs to the lungs, help achieve higher concentration of drugs at the site of action, and reduce the dosing frequency and systemic side effects associated with oral therapies. This has led to a growing demand for advanced pulmonary delivery devices such as metered dose inhalers, dry powder inhalers, nebulizers, and other systems across the world.
Patent expiration of blockbuster respiratory drugs has emerged as a major challenge restraining the growth of the pulmonary drug delivery systems market. For example, the patents of GlaxoSmithKline's Advair Diskus expired between 2013-2015 across different regions. Advair Diskus was one of the top-selling respiratory drug which generated over $5 billion in annual revenues for GSK. Similarly, patents of other blockbuster drugs such as Symbicort and Spiriva are scheduled to expire during 2018-2022. This has opened opportunities for generic versions and alternate drug delivery systems. However, it has reduced the profitability of patented product developers and inhaler manufacturers who derived a major portion of their revenues from these drugs. The availability of low-cost generics is also decreasing the demand and sales of branded pulmonary delivery devices in the market. This poses significant near-term challenges for established market players.
In the segment specifically devoted to leading companies in the Pulmonary Drug Delivery Systems Market of the market analysis document, our researchers provide a summary of the financial statements of all the major companies, covering their noteworthy developments, product benchmarking, and SWOT analysis. The corporate profile copy also includes financial information and a business summary. The businesses in this area can be customized to match the unique needs of the client.
Some of the Top Players in Pulmonary Drug Delivery Systems Market:
3M Health Care, Allied Healthcare Products, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., Koninklijke Philips N.V.
Global Pulmonary Drug Delivery Systems Market, By Product Type:
Dry Powder Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Global Pulmonary Drug Delivery Systems Market, By Application:
Chronic Obstructive Pulmonary Disease (COPD)
Global Pulmonary Drug Delivery Systems Market, By Distribution Channel:
Regional Analysis -
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
Latin America (Colombia, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Buy Now and Get a Discount on this Report @ https://www.coherentmarketinsights.com/insight/buy-now/3952
The growing transition towards digital healthcare models presents new opportunities for players in the pulmonary drug delivery systems market. Technologies such as electronic monitoring devices, mobile applications, and web-based platforms allow continuous monitoring of patients' medication use and symptoms. This helps clinicians optimize drug therapies in real-time. Several companies are now developing "smart" inhalers integrated with such digital technologies. For instance, Adherium launched "SmartTrack"-an add-on sensor for inhalers that transmits usage data via Bluetooth. Likewise, Cohero Health offers a connected asthma inhaler along with a mobile app. As digital health models become more pervasive, there will be increased demand for integrated devices with remote monitoring capabilities. This provides an opportunity for market players to commercialize innovative "digital-first" pulmonary drug delivery portfolios tailored for the connectivity era. Partnerships with digital health companies and payers can further aid successful adoption of such solutions.
One of the major trends shaping the future of pulmonary drug delivery systems is the increasing focus on personalized therapies. With advancements in genomics, biomarkers and 3D printing, there is a shift from "one-size-fits-all" treatment approaches to more customized solutions tailored to individual patient needs, biology and drug response. Several companies are developing personalized dry powder and metered-dose inhalers that can be calibrated precisely based on a person's inspiratory flow profile and disease condition. Likewise, companion diagnostics are being integrated with dry powder inhalers to enable dosage adjustments according to a patient's genetic makeup and mutation levels. 3D printing also offers opportunities to manufacture customized reservoirs, capsules and active ingredients for inhalers. This emerging trend towards personalized pulmonary drug delivery holds potential to transform patient outcomes, therapy management and market dynamics.
Reasons to Purchase this Report:
✔ Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
✔ Reports provide opportunities and threats faced by suppliers in the Pulmonary Drug Delivery Systems industry around the world.
✔ The report shows regions and sectors with the fastest growth potential.
✔A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
✔ The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
✔ This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/3952
Questions Answered by the Report:
(1) Which are the dominant players of the Pulmonary Drug Delivery Systems Market?
(2) What will be the size of the Pulmonary Drug Delivery Systems Market in the coming years?
(3) Which segment will lead the Pulmonary Drug Delivery Systems Market?
(4) How will the market development trends change in the next five years?
(5) What is the nature of the competitive landscape of the Pulmonary Drug Delivery Systems Market?
(6) What are the go-to strategies adopted in the Pulmonary Drug Delivery Systems Market?
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
✉ Email: firstname.lastname@example.org
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Drug Delivery Systems Market is Booming Growth Prospects, Incredible Demand and Business Strategies 2023-2030 | 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca here
News-ID: 3312542 • Views: …
More Releases from Coherent Market Insights
Engineered Wood Market Share, Size, Financial Summaries Analysis from 2024-2031 …
Global Engineered Wood Market Growing Demand and Growth Opportunity 2024-2031: The Latest Report, titled "Engineered Wood Market" Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The Engineered Wood market has been growing significantly in recent years,
Cryogenic Valves Market Share 2024 Size, Business Improving Strategies, Current …
Global Cryogenic Valves Market Growing Demand and Growth Opportunity 2024-2031: The Latest Report, titled "Cryogenic Valves Market" Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The Cryogenic Valves market has been growing significantly in recent years,
Battery Management System Market Share 2024 by Key Suppliers, Pricing Trends, Gl …
Global Battery Management System Market Growing Demand and Growth Opportunity 2024-2031: The Latest Report, titled "Battery Management System Market" Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The Battery Management System market has been growing significantly
Water Treatment Chemicals Market Sales Outlook, Up-to-date Development Data and …
Global Water Treatment Chemicals Market Growing Demand and Growth Opportunity 2024-2031: The Latest Report, titled "Water Treatment Chemicals Market" Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The Water Treatment Chemicals market has been growing significantly
More Releases for Pulmonary
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Embolism - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Embolism - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments